Positron Emission Tomography

The TFS Phase I Unit offers the possibility to perform PET studies. PET studies can provide patient data early in the clinical drug development stage and therefore shorten the time span to proof of concept. PET's contribution to early drug development studies includes:

• Monitoring the drug-effect, including dose-response evaluations where the occupancy on a receptor system is monitored at increased doses and at different times after the dosing. Labelling a potential candidate drug to obtain organ PK, including studies of drug entry over blood-brain barrier.
• Micro-dosing provides an early opportunity to test the candidate drug on man.

TFS is supporting the development of labelling and the validation of new PET tracers. The development time of labelling procedures, including GMP documentation, depends on the molecule. That is why the planning and coordination should start as early as possible. Between 80% and 90% of suggested organic molecules can be labelled with 11C. This offers the possibility to involve the PET team in later stages if required.

 TFS enters Positron Emission Tomography Agreement (English)

 El Instituto de Alta Tecnología - CRC se alía con Trial Form Support (Spanish)